Hodgkin lymphoma version 1.2017

Richard T. Hoppe, Ranjana H. Advani, Weiyun Z. Ai, Richard F. Ambinder, Patricia Aoun, Celeste M. Bello, Cecil M. Benitez, Karl Bernat, Philip J. Bierman, Kristie A. Blum, Robert Chen, Bouthaina Dabaja, Andres Forero, Leo I. Gordon, Francisco J. Hernandez-Ilizaliturri, Ephraim P. Hochberg, Jiayi Huang, Patrick B. Johnston, Mark S. Kaminski, Vaishalee P. KenkreNadia Khan, David G. Maloney, Peter M. Mauch, Monika Metzger, Joseph O. Moore, David Morgan, Craig H. Moskowitz, Carolyn Mulroney, Matthew Poppe, Rachel Rabinovitch, Stuart Seropian, Mitchell Smith, Jane N. Winter, Joachim Yahalom, Jennifer Burns, Ndiya Ogba, Hema Sundar

Research output: Contribution to journalReview articlepeer-review

45 Scopus citations

Abstract

This portion of the NCCN Guidelines for Hodgkin lymphoma (HL) focuses on the management of classical HL. Current management of classical HL involves initial treatment with chemotherapy or combined modality therapy followed by restaging with PET/CT to assess treatment response using the Deauville criteria (5-point scale). The introduction of less toxic and more effective regimens has significantly advanced HL cure rates. However, long-term follow-up after completion of treatment is essential to determine potential long-term effects.

Original languageEnglish (US)
Pages (from-to)608-638
Number of pages31
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume15
Issue number5
DOIs
StatePublished - May 1 2017
Externally publishedYes

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Hodgkin lymphoma version 1.2017'. Together they form a unique fingerprint.

Cite this